Buscar resultados de ensayos clínicos
Prostatic Neoplasms, Castration-Resistant - 21 Studies Found
Estado | Estudiar |
Not yet recruiting |
Nombre del estudio: Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA) Condición: Prostatic Cancer, Castration-Resistant Fecha: 2016-08-08 Intervenciones: Drug: SXL01 |
Recruiting |
Nombre del estudio: Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer Condición: Prostate Cancer Fecha: 2015-04-15 Intervenciones:
|
Recruiting |
Nombre del estudio: Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer Condición: Metastatic Castration-Resistant Prostatic Cancer Fecha: 2014-09-30 Intervenciones:
|
Terminated |
Nombre del estudio: F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Condición: Castration-resistant Prostate Cancer Fecha: 2013-08-01 Intervenciones: Device: F-Choline-PET |
Completed |
Nombre del estudio: Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer Condición:
Fecha: 2007-10-09 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Condición:
|
Not yet recruiting |
Nombre del estudio: Combination Study of Guadecitabine and Pembrolizumab. Condición:
Fecha: 2016-11-02 Intervenciones:
|
Recruiting |
Nombre del estudio: Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases Condición: Castration-Resistant Prostatic Cancer Fecha: 2015-03-20 Intervenciones: Drug: Radium-223 dichloride, (Xofigo, BAY88-8223) Dosage and treatment duration according to the decisio |
RECRUITING |
Nombre del estudio: Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy Condición: Fecha: 2024-05-16 Intervenciones: To evaluate the tolerability and safety of 225Ac-PSMA I&T in patients with metastatic prostate cancer |
NOT_YET_RECRUITING |
Nombre del estudio: Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer Condición: Prostatic Neoplasms, Castration-Resistant Fecha: 2024-05-16 Intervenciones: TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol |